Key opportunities include outsourced testing for complex biologics, AI-enabled high-throughput platforms, multi-omics biomarker services, bioequivalence testing for biosimilars, and expanding demand for monoclonal antibodies, cell and gene therapies, particularly in Asia-Pacific.
Large Molecule Bioanalytical Testing Services Market
Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) — The “Large Molecule Bioanalytical Testing Services Market by Type of Testing, Type of Modality, End-user, and Geographical Regions – Trends and Forecast, Till 2035” has been added to ResearchAndMarkets.com’s offering.
The global large molecule bioanalytical testing services market is projected to grow from USD 3.11 billion in 2026 to USD 5.88 billion by 2035, representing a compound annual growth rate (CAGR) of 7.3% during the forecast period. Market expansion is being supported by growing biologics pipelines, rising demand for personalized therapies, advances in analytical technologies, and increased outsourcing by pharmaceutical and biotechnology companies.
Market Growth and Key Trends
Large molecule bioanalytical testing supports the assessment of biologic therapies throughout the drug development lifecycle, including safety, efficacy, pharmacokinetics, pharmacodynamics, bioequivalence, biomarker analysis, and regulatory submissions. Demand for these services is increasing as developers advance monoclonal antibodies, cell therapies, gene therapies, biosimilars, fusion proteins, and viral-based therapies.
Pharmaceutical and biotechnology companies are increasingly outsourcing bioanalytical testing to contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Outsourcing provides access to specialized scientific expertise, advanced infrastructure, high-throughput technologies, validated analytical platforms, and regulatory capabilities while helping sponsors control costs and accelerate development timelines.
Technological advances in mass spectrometry, chromatography, immunoassays, laboratory automation, artificial intelligence, and multi-omics are improving analytical sensitivity, throughput, reproducibility, and data quality. The integration of AI with biomarker discovery and validation is also strengthening the role of large molecule bioanalytical testing services in precision medicine and targeted therapy development.
Market Challenges
Despite favorable growth prospects, the large molecule bioanalytical testing services market faces operational and regulatory challenges. Advanced biologic modalities require highly specialized analytical methods, sophisticated instrumentation, validated workflows, and experienced scientific personnel. Evolving requirements for method development, validation, data integrity, and regulatory compliance can also increase project complexity and operating costs.
Additional barriers include biological sample variability, biomarker standardization issues, assay sensitivity limitations, reproducibility concerns, and shortages of qualified bioanalytical professionals. These factors may affect testing capacity, turnaround times, analytical accuracy, and the scalability of service providers.
Large Molecule Bioanalytical Testing Services Market Segmentation
- By testing type: Pharmacokinetics, pharmacodynamics, bioequivalence, and other tests
- By modality: Monoclonal antibodies, cell therapies, gene therapies, biosimilars, fusion proteins, traditional viral-based therapies, and other biologics
- By end user: Pharmaceutical and biotechnology companies, CROs and CDMOs, and academic and research institutes
- By region: North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America
Key Segment Insights
Pharmacokinetics currently represents the largest testing segment, accounting for approximately 45% of market revenue. Its leadership is supported by the importance of pharmacokinetic studies in dose optimization, efficacy evaluation, safety monitoring, and regulatory submissions. Bioequivalence testing is expected to record the fastest growth as healthcare systems and drug developers expand access to biosimilars and seek to reduce treatment costs.
Pharmaceutical and biotechnology companies are projected to contribute nearly 50% of market revenue in 2026, supported by substantial research and development investment and expanding biologics pipelines. CROs and CDMOs are forecast to register the highest end-user growth, with an anticipated CAGR of 8.6%, as outsourcing becomes increasingly important to biologic drug development strategies.
Monoclonal antibodies account for approximately 45% of the large molecule bioanalytical testing services market. Continued investment in monoclonal antibody programs across oncology, immunology, infectious diseases, and other therapeutic areas is expected to sustain demand for specialized analytical services through 2035.
Regional Market Outlook
North America is expected to remain the largest regional market and account for approximately 50% of global revenue by 2035. The region benefits from a strong concentration of pharmaceutical and biotechnology companies, advanced research infrastructure, extensive biologics development activity, and an established regulatory environment.
Asia-Pacific is projected to be the fastest-growing region, expanding at a CAGR of 8.6% during the forecast period. Growth is being driven by increasing clinical trial activity, expanding pharmaceutical and biotechnology research, healthcare innovation investment, and the region’s growing role as an outsourcing destination for drug development and bioanalytical testing.
Competitive Landscape
Companies active in the large molecule bioanalytical testing services market include BioAgilytix, Catalent, Charles River Laboratories, Clean Cells, Coriolis Pharma, Eurofins, Genezen, SGS, Solvias, Texcell, and WuXi AppTec. Competition is influenced by analytical capabilities, modality coverage, technology portfolios, regulatory expertise, geographic reach, laboratory capacity, and the ability to support complex biologics programs.
Report Coverage
The market report provides revenue forecasts and opportunity analysis by testing type, modality, end user, and geographic region. It also examines the service provider landscape by workflow, technology, company size, headquarters location, portfolio strength, and service diversity. Company profiles include operational information, management details, service portfolios, and strategic initiatives.
The research incorporates primary discussions with bioanalytical industry stakeholders in the United States, Canada, France, Singapore, and Australia. It evaluates market drivers, restraints, opportunities, competitive conditions, emerging trends, regional performance, and the principal challenges affecting large molecule bioanalytical testing service providers.
Key Benefits of the Market Report
- Detailed market sizing and revenue forecasts through 2035
- Segment-level analysis across testing types, biologic modalities, end users, and regions
- Assessment of market growth drivers, barriers, opportunities, and challenges
- Competitive analysis and profiles of prominent service providers
- Supporting Excel data packs for analytical modules
- Up to 15% complimentary content customization
- Report walkthrough with the research team
- Complimentary update when the report is more than six months old
The report is designed to support pharmaceutical companies, biotechnology developers, CROs, CDMOs, investors, research organizations, and market entrants in evaluating the global large molecule bioanalytical testing services market, identifying high-growth opportunities, and developing informed commercial strategies.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 263 |
| Forecast Period | 2026-2035 |
| Estimated Market Value (USD) in 2026 | $3.11 Billion |
| Forecasted Market Value (USD) by 2035 | $5.88 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes, but is not limited to:
- BioAgilytix
- Catalent
- Charles River Laboratories
- Clean Cells
- Coriolis Pharma
- Eurofins
- Genezen
- SGS
- Solvias
- Texcell
- Wuxi AppTec
For more information about this report visit https://www.researchandmarkets.com/r/yo0zdk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Large Molecule Bioanalytical Testing Services Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
